Brian A Gordon

List of Publications by Year
in descending order

193 papers	7,887 citations	81900 39 h-index	56724 83 g-index
204 all docs	204 docs citations	204 times ranked	9147 citing authors

#	Article	IF	Citations
1	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
2	Beta-Amyloid Moderates the Relationship Between Cortical Thickness and Attentional Control in Middle- and Older-Aged Adults. Neurobiology of Aging, 2022, 112, 181-190.	3.1	3
3	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	9.0	15
4	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
5	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of Disease, 2022, 166, 105662.	4.4	21
6	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
7	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
8	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228.	4.2	27
9	Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimerâ€™s disease. Brain Communications, 2022, 4, .	3.3	4
10	Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome. Frontiers in Neuroscience, 2022, 16, 795317.	2.8	2
11	Effect of Race on Prediction of Brain Amyloidosis by Plasma AÎ²42/AÎ²40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.1	63
12	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
13	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 776-785.	1.3	30
14	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
15	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. Journal of Cognitive Neuroscience, 2021, 33, 279-302.	2.3	10
16	Cerebrospinal fluid AÎ²42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. Neurobiology of Aging, 2021, 98, 116-123.	3.1	7
17	Socioeconomic Status Mediates Racial Differences Seen Using the <scp>AT(N)</scp> Framework. Annals of Neurology, 2021, 89, 254-265.	5.3	42
18	Flortaucipir (tau) PET in LGI1 antibody encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 491-497.	3.7	7

#	Article	IF	Citations
19	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4
20	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	7.6	66
21	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. Journal of Neuroimmunology, 2021, 352, 577474.	2.3	2
22	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	1.7	18
23	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87.	1.1	17
24	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. Psychological Science, 2021, 32, 849-860.	3.3	8
25	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
26	Comparing amyloid-Î² plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	7.7	15
27	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	12.8	43
28	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 153.	6.2	3
29	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	3.1	9
30	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.1	35
31	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.8	12
32	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
33	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). Alzheimer Disease and Associated Disorders, 2021, 35, 164-168.	1.3	30
34	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 825-837.	1.3	22
35	The interaction of APOE genotype and amyloidâ€Î² PET predicts PET but not CSF measures of tauopathy in regions of high APOE mRNA expression. Alzheimer's and Dementia, 2021, 17, .	0.8	0
36	Sharper in the morning: Cognitive sundowning revealed with highâ€frequency smartphone testing. Alzheimer's and Dementia, 2021, 17, .	0.8	3

#	Article	IF	Citations
37	Ageâ€related atrophy persists after screening for preclinical Alzheimer disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
38	Association between personality and tau-PET binding in cognitively normal older adults. Brain Imaging and Behavior, 2020, 14, 2122-2131.	2.1	21
39	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. Neurobiology of Aging, 2020, 96, 165-175.	3.1	13
40	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
41	Predicting dysfunctional age-related task activations from resting-state network alterations. NeuroImage, 2020, 221, 117167.	4.2	32
42	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
43	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 96, 233-245.	3.1	20
44	Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center. Alzheimer's and Dementia, 2020, 16, e037136.	0.8	0
45	Mass spectrometry measures of plasma AÎ², tau and Pâ€tau isoformsâ€™ relationship to amyloid PET, tau PET, and clinical stage of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037518.	0.8	6
46	Global system segregation enhances reserve in normal aging and Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037930.	0.8	0
47	Solanezumab inâ€depth outcomes. Alzheimer's and Dementia, 2020, 16, e038028.	0.8	3
48	Gantenerumab inâ€depth outcomes. Alzheimer's and Dementia, 2020, 16, e038049.	0.8	2
49	Tau kinetics in Alzheimer disease and primary tauopathies. Alzheimer's and Dementia, 2020, 16, e039109.	0.8	0
50	Overview of dominantly inherited AD and topâ€line DIANâ€TU results of solanezumab and gantenerumab. Alzheimer's and Dementia, 2020, 16, e041129.	0.8	4
51	Socioeconomic status mediating sex and racial differences using the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e041229.	0.8	1
52	Brain network dysfunction associated with blood neurofilament light chain in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041586.	0.8	1
53	Tauopathy in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041683.	0.8	0
54	APOE4 status influences the amyloid and tau relationship. Alzheimer's and Dementia, 2020, 16, e042093.	0.8	0

#	Article	IF	Citations
55	Socioeconomic status mediates racial differences seen using the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e043216.	0.8	0
56	Headâ€toâ€head comparison of [¹⁸F]MKâ€6240 and [¹⁸F]flortaucipir (AVâ€1451) in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e044688.	0.8	1
57	Default mode network dedifferentiation predicts cognitive performance in Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e044790.	0.8	1
58	Crossâ€modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e045905.	0.8	0
59	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomalâ€dominant Alzheimer disease depend on imaging modality. Alzheimer's and Dementia, 2020, 16, e045942.	0.8	0
60	Evaluation of 18 Fâ€MKâ€6240 and 18 Fâ€AVâ€1451 tau PET tracers in Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e046124.	0.8	0
61	Neurofilament light is a nonâ€specific marker of aging and white matter integrity. Alzheimer's and Dementia, 2020, 16, e046169.	0.8	0
62	Vasogenic edema in the frontostriatal tract and the anterior limb of the internal capsule predict cognitive decline in Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e046183.	0.8	0
63	A timeâ€embedding network model captures dynamic longitudinal pathology changes in a dominantly inherited Alzheimer disease population. Alzheimer's and Dementia, 2020, 16, e046335.	0.8	0
64	Investigating whether fractional anisotropy is associated with reduced reaction time cost on an attentional control task. Alzheimer's and Dementia, 2020, 16, e046462.	0.8	0
65	A comparison of the Montreal Cognitive Assessment and standard cognitive measures in the National Alzheimerâ€™s Coordinating Center and Knight Alzheimerâ€™s Disease Research Center cohorts. Alzheimer's and Dementia, 2020, 16, e046780.	0.8	1
66	Anteâ€and postmortem tau in autosomal dominant and lateâ€onset Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 2475-2480.	3.7	10
67	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	10.2	97
68	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. Cerebral Cortex, 2020, 30, 5686-5701.	2.9	22
69	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
70	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. NeuroImage: Clinical, 2020, 26, 102248.	2.7	24
71	Neurofilaments in disease: what do we know?. Current Opinion in Neurobiology, 2020, 61, 105-115.	4.2	44
72	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351

#	Article	IF	Citations
73	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 1119-1129.	2.6	14
74	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
75	High-precision plasma Î²-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659.	1.1	514
76	ICâ€Pâ€166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.8	0
77	Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals. Brain, 2019, 142, 2903-2904.	7.6	2
78	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	30.7	610
79	Author response: In vivo [¹⁸ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2019, 92, 150-150.	1.1	2
80	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-Î² Burden in Cognitively Normal Individuals in Late-Life. Journal of Alzheimer's Disease, 2019, 69, 817-827.	2.6	23
81	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	2.7	41
82	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	2.4	84
83	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. European Journal of Neurology, 2019, 26, 1235-1239.	3.3	3
84	Tau PET in autosomal dominant Alzheimerâ€™s disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	7.6	122
85	ICâ€Pâ€131: PIB BINDING TOPOGRAPHY BEST CORRELATES WITH YOUNG ADULT GLYCOLYSIS. Alzheimer's and Dementia, 2019, 15, P108.	0.8	0
86	ICâ€Pâ€094: CROSSâ€SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P82.	0.8	0
87	ICâ€Pâ€098: PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P85.	0.8	0
88	O3â€12â€01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P914.	0.8	0
89	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
90	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	9.0	227

#	Article	IF	Citations
91	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 2019, 75, 42-50.	3.1	36
92	Alzheimer disease biomarkers and synucleinopathy. Neurology, 2018, 90, 537-538.	1.1	0
93	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469.	0.8	192
94	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE Îµ4 genotype. Brain, 2018, 141, 1828-1839.	7.6	99
95	Measures of metabolism provide insights into hippocampal sclerosis. Brain, 2018, 141, 946-948.	7.6	1
96	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
97	In vivo [¹⁸ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2018, 90, e896-e906.	1.1	27
98	Brian Andrew Gordon. Lancet Neurology, The, 2018, 17, 210.	10.2	0
99	Crossâ€sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid Î² positron emission tomography pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 245-252.	2.4	49
100	Tau Kinetics in Neurons and the Human Central Nervous System. Neuron, 2018, 97, 1284-1298.e7.	8.1	381
101	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 67, 95-98.	3.1	73
102	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
103	O3â€13â€03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P1056.	0.8	0
104	ICâ€Pâ€204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P167.	0.8	1
105	P3â€251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2018, 14, P1170.	0.8	1
106	ICâ€Pâ€167: ALTERED RESTINGâ€STATE FUNCTIONAL MRI SIGNAL ENTROPY IN TEMPORAL AND PARIETAL LOBES IN SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P140.	0.8	0
107	ICâ€Pâ€162: REGIONAL CORTICAL THINNING PATTERNS IN COGNITIVELY IMPAIRED AND CONVERTER INDIVIDUALS USING OASISâ€3 DATA. Alzheimer's and Dementia, 2018, 14, P136.	0.8	0
108	ICâ€Pâ€207: EXAMINING THE ABILITY OF A TAU SPATIAL SPREAD METRIC TO INDICATE DISEASE PROGRESSION COMPARED TO AN INTENSITYâ€BASED APPROACH. Alzheimer's and Dementia, 2018, 14, P170.	0.8	0

#	Article	IF	Citations
109	ICâ€Pâ€009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19.	0.8	0
110	ICâ€02â€01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.8	0
111	ICâ€Pâ€042: RESTINGâ€STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P42.	0.8	0
112	P2â€362: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P829.	0.8	0
113	ICâ€Pâ€043: FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND LATE ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P43.	0.8	0
114	P4â€108: RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1480.	0.8	3
115	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	2.4	14
116	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 669-676.	3.7	9
117	ICâ€04â€02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETAâ€AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P7.	0.8	0
118	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
119	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	3.1	42
120	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	2.7	76
121	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology, 2018, 91, e313-e318.	1.1	68
122	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology, 2018, 91, e859-e866.	1.1	190
123	Discovery and validation of autosomal dominant Alzheimerâ€™s disease mutations. Alzheimer's Research and Therapy, 2018, 10, 67.	6.2	29
124	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 87-93.	1.3	52
125	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage, 2017, 161, 171-178.	4.2	116
126	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0

#	Article	IF	Citations
127	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 509-513.	2.6	11
128	Left caudal middle frontal gray matter volume mediates the effect of age on self-initiated elaborative encoding strategies. Neuropsychologia, 2017, 106, 341-349.	1.6	9
129	Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiology of Aging, 2017, 49, 216.e7-216.e13.	3.1	22
130	[P2â€“372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
131	[P1â€“008]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P233.	0.8	0
132	[P2â€“374]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER'S DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER'S DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P769.	0.8	0
133	[P4â€“244]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN ADâ€DEFINED REGIONS. Alzheimer's and Dementia, 2017, 13, P1370.	0.8	0
134	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.8	0
135	[ICâ€Pâ€061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P50.	0.8	0
136	[ICâ€Pâ€064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P53.	0.8	0
137	[ICâ€Pâ€138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P105.	0.8	0
138	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
139	[ICâ€Pâ€180]: FLORTAUCIPIR TAUâ€PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDTâ€JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P134.	0.8	0
140	[ICâ€Pâ€196]: TAU DISTRIBUTION IN PRECLINICAL ALZHEIMER's DISEASE: FINDINGS FROM THE KNIGHT ALZHEIMER's DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P144.	0.8	0
141	[ICâ€Pâ€205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P149.	0.8	0
142	[ICâ€01â€“02]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN ADâ€DEFINED REGIONS. Alzheimer's and Dementia, 2017, 13, P1.	0.8	0
143	[ICâ€02â€“02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P4.	0.8	0
144	[P1â€“351]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P391.	0.8	0

#	Article	IF	Citations
145	[P1â€“402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P427.	0.8	0
146	[P1â€“422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€Avâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P440.	0.8	0
147	[P2â€“345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P754.	0.8	0
148	[O1â€“02â€“01]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P184.	0.8	0
149	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
150	[O2â€“05â€“03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING. Alzheimer's and Dementia, 2017, 13, P561.	0.8	0
151	[O3â€“09â€“05]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€Avâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P922.	0.8	0
152	[ICâ€Pâ€197]: THE ASSOCIATION BETWEEN PERSONALITY AND TAU PET DEPOSITION IN COGNITIVELY NORMAL OLDER ADULTS: FINDINGS FROM THE KNIGHT ALZHEIMER DISEASE RESEARCH CENTER. Alzheimer's and Dementia, 2017, 13, P145.	0.8	0
153	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
154	Neuroimaging and Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease. , 2017, , .		0
155	Comparing Aging and Fitness Effects on Brain Anatomy. Frontiers in Human Neuroscience, 2016, 10, 286.	2.0	29
156	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.8	0
157	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimerâ€™S Disease and Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P507.	0.8	0
158	ICâ€Pâ€098: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to The Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks. Alzheimer's and Dementia, 2016, 12, P75.	0.8	0
159	P3â€234: Similarities and Differences in Patterns of [F18]â€Avâ€1451 and [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P915.	0.8	0
160	P3â€283: Functional Connectivity with Anterior Temporal Lobe Regions Ordered According to the Braak Progression Scheme Reveals Sequential Coupling to Default Mode and Then Sensory Networks. Alzheimer's and Dementia, 2016, 12, P946.	0.8	0
161	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
162	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0

#	Article	IF	Citations
163	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
164	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	3.1	80
165	A diffusion model analysis of episodic recognition in preclinical individuals with a family history for Alzheimerâ€™s disease: The adult children study.. Neuropsychology, 2016, 30, 225-238.	1.3	34
166	Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Nonâ€“Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1192.	9.0	77
167	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	5.3	82
168	Tau and Aβ² imaging, CSF measures, and cognition in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 338ra66.	12.4	560
169	ICâ€Pâ€179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB₄₂, and Cognition in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P130.	0.8	0
170	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	7.6	150
171	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
172	O1-01-01: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers. , 2015, 11, P122-P123.		0
173	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P697-P697.		0
174	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. NeuroImage: Clinical, 2015, 8, 246-252.	2.7	43
175	IC-P-020: Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers. , 2015, 11, P24-P25.		0
176	IC-P-164: Patterns of tau binding in T807-PET imaging. , 2015, 11, P110-P110.		1
177	P2-154: Patterns of tau binding in T807-PET imaging. , 2015, 11, P546-P546.		0
178	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
179	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimerâ€™s disease biomarkers. Neurobiology of Aging, 2015, 36, 1771-1779.	3.1	36
180	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.1	27

#	Article	IF	Citations
181	Spread of activation and deactivation in the brain: does age matter?. Frontiers in Aging Neuroscience, 2014, 6, 288.	3.4	14
182	Neurovascular coupling in normal aging: A combined optical, ERP and fMRI study. NeuroImage, 2014, 85, 592-607.	4.2	178
183	Prefrontal gray matter volume mediates age effects on memory strategies. NeuroImage, 2014, 90, 326-334.	4.2	50
184	Regional variability in Alzheimerâ€™s disease biomarkers. Future Neurology, 2014, 9, 131-134.	0.5	6
185	Evidence for a detrimental relationship between hypertension history, prospective memory, and prefrontal cortex white matter in cognitively normal older adults. Cognitive, Affective and Behavioral Neuroscience, 2013, 13, 405-416.	2.0	18
186	Effects of Aging and Alzheimer's Disease Along the Longitudinal Axis of the Hippocampus. Journal of Alzheimer's Disease, 2013, 37, 41-50.	2.6	32
187	he Effects of Aging and Physical Fitness on Working Memory Capacity. Korean Journal of Cognitive and Biological Psychology, 2012, 24, 107-126.	0.0	3
188	Structural correlates of prospective memory. Neuropsychologia, 2011, 49, 3795-3800.	1.6	79
189	Span, CRUNCH, and Beyond: Working Memory Capacity and the Aging Brain. Journal of Cognitive Neuroscience, 2010, 22, 655-669.	2.3	342
190	Frequency analysis of the visual steady-state response measured with the fast optical signal in younger and older adults. Biological Psychology, 2010, 85, 79-89.	2.2	21
191	Neuroanatomical correlates of aging, cardiopulmonary fitness level, and education. Psychophysiology, 2008, 45, 825-838.	2.4	140
192	Effects of measurement method, wavelength, and source-detector distance on the fast optical signal. NeuroImage, 2006, 32, 1576-1590.	4.2	125
193	Time course of activation of human occipital cortex measured with the event-related optical signal (EROS). , 2006, , .		1